{"id":6707,"date":"2025-05-22T10:56:08","date_gmt":"2025-05-22T08:56:08","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/"},"modified":"2025-05-22T10:56:10","modified_gmt":"2025-05-22T08:56:10","slug":"le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/","title":{"rendered":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie"},"content":{"rendered":"
\n
\n
\n
\n<\/figure><\/div>\n<\/div>\n

Un nouveau m\u00e9dicament pour la fibrose pulmonaire a r\u00e9duit la progression de la maladie de plus de 50% sur un traitement de 52 semaines dans deux essais cliniques. La fibrose pulmonaire est une maladie tr\u00e8s grave, avec un pronostic de vie de 3 \u00e0 5 ans apr\u00e8s le diagnostic. Mais le nouveau m\u00e9dicament, le nerandomilast (Boehringer Ingelheim), pourrait r\u00e9volutionner le traitement de la maladie apr\u00e8s plusieurs \u00e9checs de tous les nouveaux m\u00e9dicaments potentiels test\u00e9s pour cette maladie au cours de la derni\u00e8re d\u00e9cennie qui ont \u00e9chou\u00e9 dans les \u00e9tudes de phase 2 ou de phase 3.<\/p>\n

Des r\u00e9sultats positifs de deux \u00e9tudes de phase 3 sur le nerandomilast ont \u00e9t\u00e9 pr\u00e9sent\u00e9s au Congr\u00e8s annuel de l’American Thoracic Society (ATS, San Francisco, 16-21 mai). Les essais ont \u00e9t\u00e9 men\u00e9s avec des patients atteints de fibrose pulmonaire idiopathique ou de l’IPF (\u00e9tude Fibroneer-IPF) et dans une fibrose pulmonaire progressive secondaire (\u00e9tude Fibroneer-ILD). Le nouveau m\u00e9dicament est un inhibiteur s\u00e9lectif administr\u00e9 par voie orale de la phosphodiest\u00e9rase 4B, qui peut \u00e9galement \u00eatre combin\u00e9 avec des m\u00e9dicaments existants (nint\u00e9danib ou pirf\u00e9nidone).<\/p>\n

La recherche est publi\u00e9e dans le Journal de m\u00e9decine de la Nouvelle-Angleterre<\/i>.<\/p>\n

Luca Richeldi, full professor of Diseases of the Respiratory System at the Catholic University of the Sacred Heart and director of the UOC of Pulmonology at Fondazione Policlinico Gemelli IRCCS, is the global Principal Investigator (PI) and first author of the study on idiopathic pulmonary fibrosis (thus confirming his position as one of the world’s leading experts on the subject) and is one of the authors of the study on secondary Fibrose, en tant que membre du comit\u00e9 directeur.<\/p>\n

Le professeur Richeldi a d\u00e9clar\u00e9: \u00ab\u00a0La publication de ces deux \u00e9tudes repr\u00e9sente une perc\u00e9e pour la maladie, car elle ouvre une nouvelle g\u00e9n\u00e9ration de m\u00e9dicaments pour ces patients, qui ont jusqu’\u00e0 pr\u00e9sent eu des options th\u00e9rapeutiques tr\u00e8s limit\u00e9 diarrh\u00e9e).<\/p>\n

\u00ab\u00a0Dans l’IPF, le m\u00e9dicament a r\u00e9duit la progression de la maladie de plus de 50% sur la dur\u00e9e de l’essai de 52 semaines (l’essai a randomis\u00e9 1 177 patients, trait\u00e9 avec du nerandomilast 9 ou 18 mg par jour ou un placebo) et dans des formes non idiopathiques de fibrose, cela a \u00e9galement \u00e9t\u00e9 r\u00e9v\u00e9l\u00e9 pour une r\u00e9duction de la mortalit\u00e9.<\/p>\n

\u00ab\u00a0Cette double indication (pour les formes idiopathiques et secondaires de la fibrose) repr\u00e9sente une nouveaut\u00e9 car elle permettra le traitement d’un spectre plus large de pathologies, par rapport au spectre \u00e9troit de l’IPF. Des formes non idiopathiques comprennent, par exemple, les maladies pulmonaires secondaires pour les maladies auto-immunes ou l’exposition aux maladies li\u00e9es au m\u00e9dicament.\u00a0\u00bb<\/p>\n

Le professeur Richeldi a ajout\u00e9: \u00ab\u00a0Un seul m\u00e9dicament, le nerandomilast, s’est av\u00e9r\u00e9 efficace dans le traitement des pathologies jusqu’ici consid\u00e9r\u00e9 comme tr\u00e8s diff\u00e9rent. Et bien que le nerandomilast ne gu\u00e9rit pas la fibrose pulmonaire (une fois \u00e9tablie, les dommages pulmonaires ne r\u00e9gressent pas), il repr\u00e9sente une \u00e9tape majeure pour le traitement de cette condition.<\/p>\n

\u00ab\u00a0Il est \u00e9galement important d’avoir atteint un autre point final: le nouveau m\u00e9dicament retarde le d\u00e9but de l’oxyg\u00e9noth\u00e9rapie, qui – selon mon exp\u00e9rience – est extr\u00eamement invalidante pour ces patients, au point de limiter (et parfois d’essuyer) leur vie sociale, conduisant \u00e0 des effets n\u00e9gatifs importants sur leur qualit\u00e9 de vie.\u00a0\u00bb<\/p>\n

Le professeur Richeldi a conclu: \u00ab\u00a0La prochaine \u00e9tape sur laquelle nous travaillons sera une \u00e9tude de deux ans chez les patients pr\u00e9sentant la premi\u00e8re forme de la maladie, connue sous le nom d’ILA (anomalies pulmonaires interstitielles), trait\u00e9es par le nerandomilast, afin de comprendre si les \u00e9meuts pr\u00e9cliniques ou subcliniques de la maladie peuvent ralentir davantage sa procr\u00e9tion et m\u00eame d’\u00e9viter l’\u00e9mergence des sympt\u00f4mes de fibrose pulmonaire pulmonaire.\u00a0\u00bb<\/p>\n

<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Un nouveau m\u00e9dicament pour la fibrose pulmonaire a r\u00e9duit la progression de la maladie de<\/p>\n","protected":false},"author":1,"featured_media":6708,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[5067,5411,248,5410,669,5412,1715,1165],"class_list":["post-6707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-formes","tag-inhibe","tag-maladie","tag-nerandomilast","tag-peut","tag-phosphodiesterase","tag-plusieurs","tag-traiter","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"\nLe nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Un nouveau m\u00e9dicament pour la fibrose pulmonaire a r\u00e9duit la progression de la maladie de\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-22T08:56:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-22T08:56:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie\",\"datePublished\":\"2025-05-22T08:56:08+00:00\",\"dateModified\":\"2025-05-22T08:56:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\"},\"wordCount\":675,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg\",\"keywords\":[\"formes\",\"inhibe\",\"maladie\",\"nerandomilast\",\"peut\",\"phosphodiest\u00e9rase\",\"plusieurs\",\"traiter\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\",\"name\":\"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg\",\"datePublished\":\"2025-05-22T08:56:08+00:00\",\"dateModified\":\"2025-05-22T08:56:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/","og_locale":"fr_FR","og_type":"article","og_title":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org","og_description":"Un nouveau m\u00e9dicament pour la fibrose pulmonaire a r\u00e9duit la progression de la maladie de","og_url":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/","og_site_name":"RVH-Synergie","article_published_time":"2025-05-22T08:56:08+00:00","article_modified_time":"2025-05-22T08:56:10+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie","datePublished":"2025-05-22T08:56:08+00:00","dateModified":"2025-05-22T08:56:10+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/"},"wordCount":675,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg","keywords":["formes","inhibe","maladie","nerandomilast","peut","phosphodiest\u00e9rase","plusieurs","traiter"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/","url":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/","name":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg","datePublished":"2025-05-22T08:56:08+00:00","dateModified":"2025-05-22T08:56:10+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/05\/1747904169_Le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes.jpg","width":1920,"height":1280,"caption":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/le-nerandomilast-inhibe-la-phosphodiesterase-4b-peut-traiter-plusieurs-formes-de-maladie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Le nerandomilast inhibe la phosphodiest\u00e9rase 4b, peut traiter plusieurs formes de maladie"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/6707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=6707"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/6707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/6708"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=6707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=6707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=6707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}